Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Stock Information for Axcella Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Axcella Health Inc.

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.